Challenges of medication management in hospitalized patients with Parkinson's disease

Wood, Lindy D.; Neumiller, Joshua J.; Carlson, Jonathan D.; Setter, Stephen M.; Corbett, Cynthia F.
December 2010
American Journal of Health-System Pharmacy;12/1/2010, Vol. 67 Issue 23, p2059
Academic Journal
In this article the authors discuss aspects of the challenges faced by pharmacists and other health care teams in managing the medications of hospitalized patients with Parkinson's disease (PD). The authors offer an overview of PD, which reportedly affects over one million residents in the U.S., as well as its pharmacotherapy and medications to be used including anticholinergics, dopamine agonists, and amantadine. They also investigate the retrospective audit of medical records of PD patients.


Related Articles

  • Effects of an integrated clinical information system on medication safety in a multi-hospital setting. Mahoney, Charles D.; Berard-Collins, Christine M.; Coleman, Reid; Amaral, Joseph F.; Cotter, Carole M. // American Journal of Health-System Pharmacy;9/15/2007, Vol. 64 Issue 18, p1969 

    Purpose. The implementation of vendorbased integrated clinical information technology was studied, and its effect on medication errors throughout the medication-use process in a health care system was evaluated. Methods. The integrated systems selected for implementation included computerized...

  • Modafinil: Parkinson Disease-Related Somnolence. Generali, Joyce A.; Cada, Dennis J. // Hospital Pharmacy;Jul/Aug2014, Vol. 49 Issue 7, p612 

    This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide...

  • Antiparkinsonians/quetiapine.  // Reactions Weekly;4/1/2006, Issue 1095, p7 

    Presents a case report on the use of antiparkinsonians/quetiapine in treating parkinson's disease. Reference to the story "Catatonic Stupor During the Course of Parkinson's Disease Resolved With Electroconvulsive Therapy," by K. Suzuki, S. Awata, K. Nakagawa and T. Takano in the January 2006...

  • Valproic acid at half normal dose shows benefit in patients with retinitis pigmentosa. Richards, Cassandra A. // Ocular Surgery News;11/10/2010, Vol. 28 Issue 21, p16 

    The article discusses research on the benefits of half valproic acid (VPA) dose to patients with retinitis pigmentosa. It references a study by Shalesh Kaushal and colleagues, published in the "British Journal of Ophthalmology." The study found that 500 milligrams of VPA provides therapeutic...

  • Botulinum toxin outcomes correlate with urodynamics. Allen, Penny // Urology Times;Oct2010, Vol. 38 Issue 11, p25 

    The article offers information on the study conducted by professor Eric S. Rovner on the urodynamics of the idiopathic overactive bladder treatment with onabotulinumtoxin A. Rovner conducted a dose-ranging, phase II, and randomized controlled trial at 40 centers in North America and Europe. It...

  • Needs and opportunities for achieving optimal outcomes from the use of medicines in hospitals and health systems. Brennan, Cynthia; Donnelly, Kim; Somani, Shabir // American Journal of Health-System Pharmacy;6/15/2011, Vol. 68 Issue 12, p1086 

    The article discusses the need to achieve optimal medication-use outcomes, and refers to the Institute of Medicine (IOM) report, "To Err is Human: Building a Safer Health System". It highlights that transition of care is a source of adverse drug events (ADEs), and mentions the Joint Commission...

  • Incretin-based therapies for type 2 diabetes: a nurse's perspective. Hodgkiss, Jayne // British Journal of Nursing;11/25/2010, Vol. 19 Issue 21, p1337 

    Type 2 diabetes (T2D) is a serious and increasing problem in the UK. Large numbers of people are suffering from the disease, and its onset is occurring at younger ages, requiring prolonged treatment. Current therapies pose challenges for patients and health professionals, and new methods of...

  • diagnosis: MS. A New Era of MS Therapies?  // PN;Oct2010, Vol. 64 Issue 10, p16 

    The article focuses on the new multiple sclerosis (MS) drugs such as Gilenia from Novartis AG and Movectro from Merck Serono International SA which acquired a Russian approval. It says that Movectro has become a leading oral MS drug as compared to Gilenia, though Gilenia has been recommended by...

  • Outcry as NICE rejects Avastin for the treatment of bowel cancer--again.  // Gastrointestinal Nursing;Sep2010, Vol. 8 Issue 7, p12 

    The article reports on the denial by the National Institute for Health and Clinical Excellence (NICE) to advocate the use of Avastin in treating colorectal cancer. It states that the refusal made Great Britain the only developed country that does not provide the medicine by the state healthcare...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics